Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea

European Journal of Contraception and Reproductive Health Care

Volumn 20, Issue 4, 2015, Pages 296-307

  Witjes, Han ^a   Creinin, Mitchell D ^b   Sundström Poromaa, Inger ^c   Martin Nguyen, Allison ^d   Korver, Tjeerd ^a  

^a MSD Oss BV   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

17 estradiol; Combined oral contraceptive; Drospirenone; DRSP EE; Ethinylestradiol; MDQ; NOMAC E2; Nomegestrol acetate

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL PLUS NOMEGESTROL ACETATE; AGENTS ACTING ON THE GENITAL SYSTEM; ANDROSTANE DERIVATIVE; ESTRADIOL; ETHINYLESTRADIOL; MEGESTROL; NOMEGESTROL ACETATE; PREGNANE DERIVATIVE;

ADULT; AROUSAL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DYSMENORRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL DISTRESS QUESTIONNAIRE; MENSTRUATION DISORDER; MUSCLE CRAMP; ORAL CONTRACEPTION; PAIN; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WATER RETENTION; WITHDRAWAL BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; LONGITUDINAL STUDY; MENSTRUAL CYCLE; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ANDROSTENES; DYSMENORRHEA; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MEGESTROL; MENSTRUAL CYCLE; MIDDLE AGED; NORPREGNADIENES; PREMENSTRUAL SYNDROME; REPRODUCTIVE CONTROL AGENTS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84934764683     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2015.1016154     Document Type: Article

References (26)

1. Burke A. Nomegestrol acetate-17b-estradiol for oral contraception. Patient Prefer Adherence 2013; 7: 607-19.
2. Sitruk-Ware R , Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12: 63-75.
3. Sitruk-Ware R , Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab 2013; 27: 13-24.
4. Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985; 151: 868-77.
5. D e Lignieres B , Basdevant A , Thomas G , et a l. Biological effects of estradiol-17 beta in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-41.
6. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511-8.
7. Stanczyk F Z, Archer D F, Bhavnani B R. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: Pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013; 87: 706-27.
8. Ruan X, Seeger H , Mueck AO. The pharmacology of nomegestrol acetate. Maturitas 2012; 71: 345-53.
9. Mansour D , Verhoeven C , Sommer W , et a l. Effi cacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011; 16: 430-43.
10. Westhoff C , Kaunitz AM , Korver T , et a l. Effi cacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17beta-estradiol: A randomized controlled trial. Obstet Gynecol 2012; 119: 989-99.
11. Moos RH. Menstrual Distress Questionnaire Manual. Los Angeles, CA: Western Psychological Services; 1991.
12. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9-21.
13. Mallinckrodt CH, Lane PW, Schnell D , et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Info J 2008; 24: 303-19.
14. Zhang H , Lu N , Feng C , et a l. On fi tting generalized linear mixed-effects models for binary responses using different statistical packages. Stat Med 2011: 30; 2562-72.
15. SAS Institute Inc. S AS/STAT User's Guide. Cary, NC: SAS Institute Inc; 2011.
16. Duijkers IJM, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17b-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care 2010; 15: 314-325.
17. Gerrits M ,Schnabel PG, Post TM, Peeters PAM. Pharmacokinetic profi le of nomegestrol acetate and 17 - Estradiol after multiple and single dosing in healthy women. Contraception 2013; 87: 193-200.
18. Blode H, Wuttke W , Loock W , Rö ll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000; 5: 256-64.
19. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311-9.
20. Rapkin A J, Shelley N , Sorger S N, Winer S A. Drospirenone/ethinylestradiol. Drugs Today 2008; 44(2): 133-45.
21. Christin-Maitre S, Serfaty D , Chabbert-Buffet N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17beta-estradiol (NOMAC/E2): A double-blind, randomized study. Hum Reprod 2011; 26: 1338-47.
22. Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 mug/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 mug/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol 2012; 162: 91-5.
23. Anttila L , Neunteufel W, Petraglia F , et a l. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 mug compared with a 21/7 regimen of desogestrel 150 mug/ethinylestradiol 20 mug: A pooled analysis. Clin Drug Investig 2011; 31: 519-25.
24. Anttila L, Kunz M , Marr J. Bleeding pattern with drospirenone 3 mg-ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg-ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009; 80: 445-51.
25. Ross C, Coleman G, Stojanovska C. Factor structure of the modifi ed Moos Menstrual Distress Questionnaire: Assessment of prospectively reported follicular, menstrual and premenstrual symptomatology. J Psychosom Obstet Gynaecol 2003; 24: 163-74.
26. Van Der Ploeg HM. The factor structure of the Menstrual Distress Questionnaire-Dutch. Psychol Rep 1990; 66: 707-14.